SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

TOVX

Theriva Biologics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor upcoming FDA End-of-Phase 2 meeting for VCN-01 in PDAC in 1H 2026, which could de-risk the pivotal trial design. The SYN-020 licensing deal de-risks development costs but removes a potential pipeline asset.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.1800
T+0 close · Mar 12, 2026 · via day close
Latest settled
+44.44%
T+60 · $0.2600
Vs SPY
+33.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $0.1800entry
  2. T+1 · 8mo ago 0.00%α +0.60% · $0.1800
  3. T+5 · 8mo ago +5.56%α +6.53% · $0.1900
  4. T+20 · 7mo ago +27.78%α +25.80% · $0.2300
  5. T+60 · 5mo ago +44.44%α +33.75% · $0.2600
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tied to VCN-01's Phase 2b trial success, reduced R&D spending, and a licensing deal for SYN-020 that brings $300,000 upfront and up to $38 million in potential milestones. The company has $15.2 million in cash as of February 2026, providing runway into Q1 2027.

Key Financial Metrics

EPS
$-2.08
Deal Value
$38.0M

Key Facts

  • VCN-01 achieved primary survival and safety endpoints in Phase 2b trial, triggering a $9.0 million contingent consideration expense
  • Licensed SYN-020 to Rasayana Therapeutics for $300k upfront, up to $38M in milestones, and tiered single-digit royalties
  • R&D expenses decreased 28% YoY to $8.6M due to trial completions
  • General and administrative expenses doubled to $15.4M, driven by the contingent consideration adjustment
  • Cash balance increased to $15.2M as of February 26, 2026, funding operations into Q1 2027
  • Audited financials include a going concern qualification from auditors

Financial Impact

Net loss attributable to common stockholders was $25.2M in 2025 vs $25.7M in 2024; $9.0M non-cash charge from VCN-01 trial success inflated G&A expenses

net_lossgeneral_and_administrative_expensecash_runwaycontingent_liability

Risk Factors

  • Going concern qualification in audited financials indicates liquidity risk despite current cash runway
  • Heavy reliance on successful clinical development of VCN-01 with no near-term revenue prospects
  • Market cap of $8M appears disconnected from fundamentals given lack of revenue and ongoing losses

Market Snapshot

Exchange
NYSE

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3254568

Track record

11 reports on TOVX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026